Here we assess the resistance/sensitivity profiles of mutations that arose in patient derived-cell ALCL lines continually exposed to either crizotinib or the 2nd generation ALK/IGF-1R inhibitor ceritinib (LDK378; FDA approved in 2014 for treating ALK+ NSCLC patients who failed crizotinib) [25]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.